Protective effect of CV247 against cisplatin nephrotoxicity in rats

Human and Experimental Toxicology

Volumn 33, Issue 8, 2014, Pages 789-799

  Mathe C ^a   Szenasi G ^a   Sebesteny A ^b   Blazovics A ^a   Szentmihalyi K ^c   Hamar, P ^a   Albert, M ^d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SZENT ISTVÁN UNIVERSITY   (Hungary)

^c Eötvös Loránd Research Network   (Hungary)

^d Vetmed Laboratory Ltd   (Hungary)

Author keywords

antioxidant; cisplatin; cyclooxygenase 2; nephrotoxicity; salicylate

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; CISPLATIN; COBALT; COPPER; CREATININE; CV 247; CYCLOOXYGENASE 2; FREE RADICAL; GLUCONATE COPPER; IRON; MANGANESE; MOLYBDENUM; PLATINUM; PROSTAGLANDIN SYNTHASE; PROTECTIVE AGENT; SALICYLATE SODIUM; SELENIUM; UNCLASSIFIED DRUG; ZINC; ANTIOXIDANT; BIOLOGICAL MARKER; GLUCONIC ACID; METAL; PTGS2 PROTEIN, RAT; REACTIVE OXYGEN METABOLITE; CUPROUS ION; CV247; CYCLOOXYGENASE 2 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOLUMINESCENCE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FLUID INTAKE; FOOD DEPRIVATION; FOOD INTAKE; IMMUNOREACTIVITY; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; LONG TERM CARE; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; BLOOD; CELL PROTECTION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; TIME; WISTAR RAT; ANIMAL TISSUE; CELL INFILTRATION; CISPLATIN INDUCED NEPHROTOXICITY; COMPARATIVE STUDY; EPITHELIUM; HEAVY METAL BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; OXIDATION REDUCTION POTENTIAL; RANDOMIZED CONTROLLED TRIAL; TISSUE INJURY; WEIGHT GAIN;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; CYCLOOXYGENASE 2; CYTOPROTECTION; DISEASE MODELS, ANIMAL; GLUCONATES; KIDNEY; KIDNEY DISEASES; MALE; METALS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SODIUM SALICYLATE; TIME FACTORS;

RATTUS;

EID: 84904740539     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327113480972     Document Type: Article

References (47)

1. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005 ; 23: 1118-1124
2. Pignon JP, Syz N, Posner M, et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anti-Cancer Drug. 2004 ; 15: 331-340
3. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012 ; 30: 1692-1698
4. Setton J, Wolden S, Caria N, et al. Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. Head Neck. 2012 ; 34: 753-757
5. Rosa DD, Medeiros LR, Edelweiss MI, et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database of Syst Rev. 2012 6: CD005342
6. Boni C, Tiseo M, Boni L, et al. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer. 2012 ; 106: 658-665
7. Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer (Amsterdam, Netherlands). 2008 ; 59: 1-11
8. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New Engl J Med. 2002 ; 346: 85-91
9. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003 ; 4: 889-901
10. Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007 ; 334: 115-124
11. Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of Cisplatin nephrotoxicity. Toxins. 2010 ; 2: 2490-2518
12. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European society of clinical pharmacy special interest group on cancer care. Cancer Chemother Pharmacol. 2008 ; 61: 903-909
13. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008 ; 73: 994-1007
14. Lameire N, Kruse V, Rottey S. Nephrotoxicity of anticancer drugs - an underestimated problem?. Acta Clin Belg. 2011 ; 66: 337-345
15. Berns JS, Ford PA. Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin Nephrol. 1997 ; 17: 54-66
16. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010 ; 30: 570-581
17. de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003 ; 88: 1199-1206
18. Mathe C, Bohacs A, Duffek L, et al. Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J. 2011 ; 37: 888-894
19. Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 1984 ; 25: 753-758
20. Pabla N, Murphy RF, Liu K, et al. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009 ; 296: F505 - F511
21. Yonezawa A, Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 2011 ; 81: 563-568
22. Katsuda H, Yamashita M, Katsura H, et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharmacol Bull. 2010 ; 33: 1867-1871
23. Filipski KK, Mathijssen RH, Mikkelsen TS, et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Therapeut. 2009 ; 86: 396-402
24. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol. 2009 ; 61: 223-242
25. El-Beshbishy HA, Bahashwan SA, Aly HA, et al. Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes. Eur J Pharmacol. 2011 ; 668: 278-284
26. Shahbazi F, Dashti-Khavidaki S, Khalili H, et al. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J Pharm Pharmaceut Sci. 2012 ; 15: 112-123
27. Tarladacalisir YT, Kanter M, Uygun M. Protective effects of vitamin C on cisplatin-induced renal damage: a light and electron microscopic study. Ren Fail. 2008 ; 30: 1-8
28. Fatima S, Arivarasu NA, Mahmood R. Vitamin C attenuates cisplatin-induced alterations in renal brush border membrane enzymes and phosphate transport. Human Exp Toxicol. 2007 ; 26: 419-426
29. De Martinis BS, Bianchi MD. Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats. Pharmacol Res. 2001 ; 44: 317-320
30. Antunes LM, Darin JD, Bianchi MD. Protective effects of vitamin c against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res. 2000 ; 41: 405-411
31. Ognjanovic BI, Djordjevic NZ, Matic MM, et al. Lipid peroxidative damage on Cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium. Int J Mol Sci. 2012 ; 13: 1790-1803
32. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004 ; 195: 221-230
33. Ulubas B, Cimen MY, Apa DD, et al. The protective effects of acetylsalicylic acid on free radical production in cisplatin induced nephrotoxicity: an experimental rat model. Drug Chem Toxicol. 2003 ; 26: 259-270
34. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int. 2004 ; 65: 490-499
35. Li G, Sha SH, Zotova E, et al. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Investig. 2002 ; 82: 585-596
36. Toloudi M, Spachidou M, Chatziioannou M, et al. The impact of CV247 component on human cancer cell lines. J Clin Studies. 2011 ; 3: 62-69
37. Toloudi M, Apostolou P, Chatziioannou M, et al. Effectiveness of CDDP and CV247 combination, on colon and breast carcinomas. J Clin Studies. 2012 ; 4: 36-42
38. Hanigan MH, Gallagher BC, Taylor PT. Cisplatin nephrotoxicity: inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney. Am J Obstet Gynecol. 1996 ; 175: 270-273
39. Mason RW, Edwards IR. Studies on the copper and zinc content of the rat kidney after treatment with cisplatin. Toxicology. 1985 ; 37: 267-274
40. Blázovics A, Kovács A, Lugasi A, et al. Antioxidant defense in erythrocytes and plasma of patients with active and quiescent Crohn disease and ulcerative colitis: a chemiluminescent study. Clin Chem. 1999 ; 45: 895-896
41. Szentmihályi K, Blázovics A, Kocsis I, et al. The effect of fat rich diet and alcohol on ion concentration in bile fluid in rats. Acta Alimentaria. 2000 ; 29: 359-366
42. May Z, Taba G, Blázovics A, et al XIth International Chemical Conference. Majdik K, ed. Cluj, Romania. Incitato Press ed: Hungarian Technical Scientific Society of Transylvania ; 2005: 354-356.
43. Verrijk R, Smolders IJ, Bosnie N, et al. Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide. Cancer Res. 1992 ; 52: 6653-6656
44. Blázovics A. Redox homeostasis, bioactive agents and transduction therapy. Curr Signal Transduct Ther. 2007 ; 2: 226-239
45. Mitchell JA, Saunders M, Barnes PJ, et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol. 1997 ; 51: 907-912
46. Quilley J, Santos M, Pedraza P. Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats. Am J Physiol Heart Circ Physiol. 2011 ; 300: H2316 - H2322
47. Lasheras C, Gonzalez S, Huerta JM, et al. Plasma iron is associated with lipid peroxidation in an elderly population. J Trace Elem Med Biol. 2003 ; 17: 171-176